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ABSTRACT
Chemotherapy with or without radiation is the standard therapy
for anaplastic thyroid cancer (ATC), although the response rate
is not high and not durable. We describe a 62-year-old male
who was diagnosed with ATC and initially treated with a thyroid-
ectomy and lymph node dissection, followed by chemotherapy.
Next generation sequencing was then performed to guide ther-
apy and the tumor was found to have BRAF and programmed
death-ligand 1 (PD-L1) positivity that was subsequently treated
with vemurafenib and nivolumab. This led to substantial regres-
sion of tumor nodules. Genomic sequencing-based approaches
to identify therapeutic targets has potential for improving out-
comes. Currently, the patient continues to be in complete radio-
graphic and clinical remission 20 months after beginning
treatment with nivolumab. The Oncologist 2017;22:1149–1151
KEY POINTS
 Programmed death-1 (PD-1)/PD-L1 immunotherapy has shown evidence of durable responses in certain malignancies such
as melanoma, lung cancer, and renal cell carcinoma.
 PD-L1 positive tumors promote autoimmunity against the tumor; therefore, PD-1/PD-L1 blockade may be beneficial.
 Molecular profiling could possibly result in improved targeted therapy for certain malignancies.
INTRODUCTION
Anaplastic thyroid cancer (ATC) is a rare disease that affects one
per million persons annually, accounting for less than 10% of all
thyroid cancers, and is responsible for half of thyroid cancer
deaths each year [1]. Patients with ATC have a median survival
of 3–5 months, and there is currently no standardized treat-
ment [1, 2]. Prior data have suggested that the combination of
cisplatin with doxorubicin is superior to doxorubicin alone, mak-
ing these commonly used agents. Despite this, the overall
response rates are typically short and the various therapies
probably do not impact overall survival at the population level.
Because of the poor prognosis and paucity of therapies,
molecular proﬁling of tumors may provide additional opportu-
nities for therapeutic targets.We describe a dramatic response
to nivolumab in a 62-year-old man with programmed death-
ligand 1 (PD-L1) positive ATC.
PATIENT HISTORY
A 62-year-old man with a past medical history of ulcerative coli-
tis (UC) and psoriasis presented to an ear, nose, and throat phy-
sician for an enlarging right-sided neck mass. The UC was
diagnosed about 3 decades ago and, after intermittent thera-
pies, was in remission. The psoriasis had been treated with inter-
mittent phototherapy and was also well controlled. The patient
underwent a ﬁne needle aspiration of the right thyroid mass and
this was consistent with thyroiditis. Two months later, he under-
went a partial right thyroidectomy due to continued growth of the
neck mass.The pathology revealed a 3.8 cm partially encapsulated
T2 N0 M0 well-differentiated papillary carcinoma with no lym-
phovascular or perineural invasion. He proceeded to have a left
thyroidectomy 1 month later and pathology showed only
Hashimoto’s thyroiditis. His thyroglobulin levels, which were
elevated before surgery, decreased but did not normalize post-
operatively. A whole-body radioiodine scan showed activity in
the thyroid bed and thus the patient subsequently received a
151.9 mCi oral dose of iodine-131 for thyroid ablation.
Nine months after the initial presentation, the patient pal-
pated a recurrent enlarging neck mass and underwent a right
modiﬁed neck dissection. The patient was found to have 1 out
of the 23 lymph nodes positive for poorly differentiated adeno-
carcinoma with extranodal extension. Immunohistochemical
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studies showed the neoplastic cells to be negative for TTF1 and
PAX 8 and positive for p63, CK 7, CK 5/6, pancytokeratin (weak),
TTF1 (focal), and EMA (weak), supporting the diagnosis of ATC.
Staging was performed with a positron emission tomography
(PET)/computed tomography fusion image that showed a 3.43
3.0 cm nodule at the level of thyroid with an elevated SUV value
of 24, a second focus of activity in the right supraclavicular
region, and nodules in the right and left upper lobes of the lung
consistent with metastatic disease.
The patient was initially treated with doxorubicin (60 mg/m2)
and cisplatin (60 mg/m2) every 3 weeks for two cycles. Unfortu-
nately, the patient tolerated therapy poorly and had evidence of
radiographic progression in the lungs. The patient was then
treated with second-line paclitaxel (175 mg/m2) and simultane-
ously underwent next generation sequencing to guide therapy.
MOLECULAR TUMOR BOARD
Genotyping Results and General Interpretation
Molecular proﬁling was performed in a Clinical Laboratory
Improvement Amendments-certiﬁed laboratory via Paradigm
Diagnostics (Paradigm Diagnostics, Phoenix, AZ, http://www.
paradigmdx.com). Sequencing results revealed a BRAF V600E
mutation, mRNA overexpression of tubulin beta 3, thymidine phos-
phorylase, and survivin. Additionally, immunohistochemistry (IHC)
was performed and the tumor was PD-L1 31, PD-L1 tumor inﬁl-
trating lymphocytes (TILs) 11, PD-1 tumor 11, and PD-1 TILs 21.
The report indicates a molecular alteration in BRAF, result-
ing in a change in the encoded amino acid from a valine to glu-
tamic acid at position/codon 600. Programmed death-ligand 1
IHC is a qualitative immunohistochemical assay using monoclo-
nal mouse anti-PD-L1, clone 223C intended for use in the
detection of PD-L1 protein in formalin-ﬁxed, parafﬁn-embed-
ded tissue. Programmed death-ligand 1 IHC positivity has been
implicated as a predictive biomarker in PD-1/PD-L1 checkpoint
blockade immunotherapy [3]. The molecular tumor board rec-
ommendations included the two independent recommenda-
tions: target BRAF V600E with vemuarfenib or PD-L1 IHC
positivity with immunotherapy, such as nivolumab.
Significance of Specific Mutation/Expression
Our patient’s tumor was positive for PD-L1, which interacts with
the PD-1 receptor on activated T cells to dampen the immuno-
logic response and decrease autoimmunity. Programmed death-1
is part of the inhibitory B7 molecules and is classiﬁed as a T-cell
checkpoint molecule. It decreases autoimmunity by inhibiting
T-cell proliferation and interferon-g, tumor necrosis factor-a, and
interleukin-2 production. Therefore, blocking PD-1/PD-L1 can help
re-establish T-cell function and promote tolerance. Nivolumab
(Fig. 1) and Pembrolizumab are two approved antibodies that tar-
get this PD-1/PD-L1 interaction. Recent studies have shown that
PD-1 blockade improved overall survival and progression-free sur-
vival for metastatic melanoma, non-small cell lung cancer (NSCLC),
and renal cell carcinoma [4].
BRAF is part of the mitogen-activated protein kinase
(MAPK) signaling pathway, which promotes oncogenesis. The
V600E mutation seen in this patient is the most common type
of BRAF mutation seen in malignancies. Sustained proliferative
signaling occurs when there is continued activation of the
MAPK pathway, which promotes cell growth and survival. In
the V600E mutation, there is a conformational change in the
G-loop activation segment of BRAF, which allows it to bind the
monomers, MEK and ERK, and remain active [5]. Blocking
BRAF with inhibitors such as vemurafenib, which was used in
this patient, could result in regression of the tumor. A study
performed by Hyman et al. suggests that BRAF V600E may be
a targetable oncogene in some nonmelanoma cancers such as
NSCLC and Langerhans’-cell histiocytosis [6].
Patient Update
Following progression of paclitaxel monotherapy, the patient
was treated with the BRAF inhibitor vemurafenib. He tolerated
therapy reasonably well, with the exception of joint aches and
generalized body aches. Within days of starting vemurafenib,
there was clinical evidence of regression of his right cervical
nodal mass, but he developed a rapidly growing new palpable
midline neck mass as well as enlargement of his right supracla-
vicular node and a PET-avid left upper lobe nodule. Based on
concurrent shrinkage of the pre-existing mass and growth in
other areas, this was felt to represent a mixed response. The
Figure 1. Programmed death-ligand 1/PD-1 interaction mediates inhibition of T-cell mediated tumor cell killing. Blockade of PD-L1 with nivolu-
mab results in reactivation of T-cell mediated tumor cell killing.
Abbreviations: CTLA-4, cytotoxic T-lymphocyte-associated protein 4; MHC, major histocompatibility complex; PD-1, programmed death
1; PD-L1, programmed death-ligand 1 (CD274 or B7-H1 protein); TCR, T-cell receptor.
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midline neck mass was resected and pathology showed dense
ﬁbrous connective tissue with poorly differentiated carcinoma
with squamoid features consistent with ATC.
Based on a mixed response to vemurafenib and given the
PD-L1 positivity, nivolumab was added to the treatment regi-
men. The patient had progressive joint and body aches, dictat-
ing discontinuation of the vemurafenib, and continued on
nivolumab monotherapy. Subsequently, clinical exam on dem-
onstrated substantial regression of the right supraclavicular
lymph node and imaging showed decrease in the size of the
previously documented pulmonary nodules.
Two months into nivolumab therapy, the patient experienced
an exacerbation of psoriasis, and this was treated successfully
with topical steroids and phototherapy. Computed tomography
scans demonstrated continued reduction of pulmonary lesions
with complete radiographic resolution (Fig. 2). Following the
12th cycle of nivolumab, the patient experienced nausea, vomit-
ing, and diarrhea, and was found to have acute colitis on colono-
scopy deemed to be grade 2 colitis. His acute colitis responded
well to a short course of prednisone taper and mesalamine. In
total, the patient received 12 cycles of nivolumab, and treatment
had been held since the exacerbation of his colitis. The patient
continues to be in complete radiographic and clinical remission
20 months after beginning treatment with nivolumab.
Potential Strategies and Implications for
Clinical Practice
The genomic landscape of thyroid cancer includes activating
mutations in BRAF and RAS, which are observed in both the
well-differentiated thyroid cancers as well as anaplastic tumors.
Anaplastic thyroid cancer also carries mutations in p53, TERT
promoter, and phosphatidylinositol 3-kinase, among others [7,
8]. However, limited data exist on immunotherapy, given the
extreme virulence and genetic complexity of ATC.
This patient harbored an activating V600E mutation in
BRAF. There was a clear clinical response indicating that the
BRAF mutation was an important driver for the tumor. Unfortu-
nately, the mixed response may have indicated genomic heter-
ogeneity or acquired resistance of a subclone. This patient also
had PD-L1 positivity in both the tumor and the tumor-
inﬁltrating lymphocytes. This case suggests that immunother-
apy in patients with ATC based upon PD-L1 evaluation provides
a therapeutic option. Observations in more patients will be
required to determine durability of response, frequency of
response, and potential resistance mechanisms.
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Figure 2. Comparison chest computed tomography scans of patient with anaplastic thyroid cancer. (A): One year after diagnosis: large left
lung nodule. (B): Fifteen months later: left lung nodule after therapy with vemurafenib followed by nivolumab.
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